North America Pulmonary Function Testing Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2024 –2031 |
 حجم السوق (السنة الأساسية) |
USD 1.53 Billion |
 حجم السوق (سنة التنبؤ) |
USD 2.47 Billion |
 CAGR |
% |
| Major Markets Players |
North America Pulmonary Function Testing Market, By Type (Hardware, Services, and Software), Patient Type (Pediatric, Adult, and Geriatric), Application (Obstructive Lung Disease and Restrictive Lung Disease), End User (Hospital, Specialty Clinics, Diagnostics Laboratories, Home Care Settings, and Others) - Industry Trends and Forecast to 2031.
North America Pulmonary Function Testing Market Analysis and Insights
The pulmonary function testing market is driven by the increasing prevalence of respiratory diseases, technological advancements, and growing demand for personalized medicine. Key trends in the market include the increasing adoption of point-of-care PFT devices, growing demand for wireless and portable PFT devices, and rising focus on personalized medicine and precision medicine. However, the market also faces challenges such as limited accessibility of PFT devices in some regions, high cost of PFT devices and consumables, complexity of PFT interpretation and analysis, and limited awareness about PFT among healthcare providers and patients.
Data Bridge Market Research analyzes that the North America Pulmonary Function Testing Market is expected to reach USD 2.47 billion by 2031 from USD 1.53 billion in 2023, growing at a CAGR of 6.1% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016–2021) |
|
Quantitative Units |
Revenue in USD Billion |
|
Segments Covered |
Type (Hardware, Services, and Software), Patient Type (Pediatric, Adult, and Geriatric), Application (Obstructive Lung Disease and Restrictive Lung Disease), End User (Hospital, Specialty Clinics, Diagnostics Laboratories, Home Care Settings, and Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
VYAIRE MEDICAL, INC., Teleflex Incorporated, CAIRE, Inc., COSMED srl, Schiller AG, PULMONE ADVANCED MEDICAL DEVICE, ndd Medical Technologies, KoKo PFT, ECO MEDICS, Morgan Scientific, Inofab Health, Data Sciences International, IngMar Medical, JK Medical System Pvt. Ltd, MEDLINE, VITALOGRAPH, and CONTEC MEDICAL SYSTEMS CO., LTD among others |
Market Definition
Pulmonary Function Testing (PFT) is a comprehensive assessment of lung function, used to diagnose and monitor respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and chronic bronchitis. The market definition of PFT includes a range of tests, including Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1), FEV1/FVC Ratio, Maximal Voluntary Ventilation (MVV), and Diffusion Capacity (DLCO). PFT is typically performed using a spirometer, a device that measures the volume and flow of air inhaled and exhaled by the patient.
North America Pulmonary Function Testing Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Respiratory Disease
The increasing prevalence of respiratory diseases is a significant driver for the global pulmonary function testing market. Conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma are becoming more common due to factors like aging populations, environmental pollutants, and lifestyle changes. As these diseases grow in prevalence, there is a heightened demand for accurate and reliable diagnostic tools to manage and monitor these conditions. Pulmonary function tests are crucial for diagnosing respiratory diseases, assessing their severity, and tracking disease progression. This increased need for regular and precise testing drives the market, as healthcare providers and patients seek advanced PFT technologies to improve respiratory health outcomes and provide effective management strategies.
- Early Detection of Respiratory Diseases
The increasing respiratory disorders of early detection is a key driver for the global Pulmonary Function Testing (PFT) market. The surge in respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis fuels the demand for pulmonary function testing. The pulmonary function tests play a crucial role in enabling early detection and efficient management of respiratory conditions, thereby improving patient outcomes and quality of life through timely intervention and treatment.
Opportunity
- Rapid Technological Advancements
The development of innovative PFT devices, particularly those integrated with AI, enhances diagnostic accuracy and efficiency, offering more reliable results in identifying pulmonary diseases. Comprehensive testing systems are becoming increasingly user-friendly and portable, making them accessible to a broader range of healthcare settings. The integration with digital health technologies, such as AI and telemedicine, allows for advanced diagnostic accuracy and predictive analytics, as well as remote monitoring through connected PFT devices, expanding the reach and impact of these tools. Advanced sensor technologies, including high-sensitivity and wearable sensors, provide continuous monitoring and real-time data collection, enabling more precise and timely interventions.
Challenges/Restraints
- High Cost of Testing Equipment
The high cost of pulmonary function testing equipment hampers market growth by restricting access for smaller healthcare facilities and hindering penetration in certain regions. The substantial investment required for purchasing and maintaining sophisticated PFT devices poses financial challenges for healthcare facilities, particularly in developing regions. This economic barrier restricts the widespread adoption and use of PFT technologies, affecting overall market growth and accessibility. Addressing these cost challenges is essential for enhancing the reach and impact of pulmonary function testing worldwide.
- Lack of Standardization and Variability in Test Results
A notable lack of uniform standards leads to variability in device specifications and test protocols, which can hinder the consistency and comparability of test results across different equipment. This variability complicates efforts to integrate PFT devices with Electronic Health Record (EHR) systems, making seamless data exchange and comprehensive patient records more difficult to achieve. Without standardized protocols, ensuring that data from various PFT devices can be accurately and efficiently integrated into EHR systems remains a complex task.
Recent Developmevnts
- In April 2024, Clario's acquisition of ArtiQ enhances its Respiratory Solutions portfolio by integrating advanced AI capabilities. This strategic move combines Clario's expertise with ArtiQ’s innovative technology to improve test quality and accelerate data processing in clinical trials. The acquisition, alongside Inofab Health, solidifies Clario's leadership in respiratory care and broadens its AI-driven clinical solutions
- In September 2023, PulmOne has launched the MiniBox+ in China, showcasing it to pulmonologists at the 2023 Annual Congress of the Chinese Thoracic Society (CTS) through our distributor HTDK. The introduction was met with great enthusiasm from attendees. Check out the exciting video highlights from the event
- In May 2023, Geratherm Medical AG, was honored as a "hidden champion" by the State Development Corporation of Thuringia (LEG). The recognition highlights the company's significant role in medical technology and its global market presence. Board member Christian Frick expressed gratitude for the accolade, noting the company's innovation in medical diagnostics, lung function measurement, stroke prevention, and incubator systems, which positions it well for future growth
- In May 2023, Vitalograph, a leader in respiratory diagnostics, has expanded its portfolio with the introduction of the Vitalograph tremoflo C-100 Oscillometer at the ATS International Conference. Developed in partnership with Thorasys, this innovative device detects small airway impairment through simple tidal breathing, enhancing the diagnosis of asthma and COPD. The tremoflo C-100 integrates with the Vitalograph Spirotrac platform, offering a comprehensive view of respiratory health and supporting accurate, portable testing in various settings
- In April 2023, Ingmar Medical introduced RespiSim Software Version 4.3 a key advancement, including improved scenario import/export, reduced simulation lag, and enhanced platform stability. These updates significantly elevate usability and performance, making it a vital tool for respiratory therapy education and training.
- In September 2022, IngMar Medical launches RespiSim eLearning, a subscription-based platform providing affordable, realistic ventilation training. Featuring a Virtual Ventilator and a suite of Cleveland Clinic courses, this new offering supports hybrid and remote education, fostering a community of educators dedicated to enhancing patient outcomes
North America Pulmonary Function Testing Market Scope
The North America pulmonary function testing market is segmented into four notable segments based on type, patient type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Hardware
- Software
- Services
On the basis of service, the North America pulmonary function testing market is segmented into hardware, software, and services.
Patient Type
- Adult
- Geriatric
- Pediatric
On the basis of patient type, the North America pulmonary function testing market is segmented into adult, geriatric, and pediatric.
Application
- Obstructive Lung Disease
- Restrictive Lung Disease
On the basis of application, the North America pulmonary function testing market is segmented into obstructive lung disease, restrictive lung disease.
End User
- Hospital
- Specialty Clinics
- Diagnostics Laboratories
- Home Care Settings
- Others
On the basis of end user, the North America pulmonary function testing market is segmented into hospital, specialty clinics, diagnostics laboratories, home care settings, and others.
North America Pulmonary Function Testing Market Regional Analysis/Insights
The North America pulmonary function testing market is segmented into four notable segments based on type, patient type, application, and end user.
The countries covered in this market report are U.S., Canada, and Mexico
U.S. is expected to dominate in the North America region due to presence of market players and improving development and research in healthcare sector. The region's early tech adoption and mature market contribute to a strong demand for advanced solutions.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of large services company and their challenges faced due to large or scarce competition from local and domestic players and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Pulmonary Function Testing Market Share Analysis
The North America pulmonary function testing market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
The major market players operating in the market are VYAIRE MEDICAL, INC., Teleflex Incorporated, CAIRE, Inc., COSMED srl, Schiller AG, PULMONE ADVANCED MEDICAL DEVICE, ndd Medical Technologies, KoKo PFT, ECO MEDICS, Morgan Scientific, Inofab Health, Data Sciences International, IngMar Medical, JK Medical System Pvt. Ltd, MEDLINE, VITALOGRAPH, and CONTEC MEDICAL SYSTEMS CO., LTD among others.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA PULMONARY FUNCTION TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES
6.1.2 EARLY DETECTION OF RESPIRATORY DISEASES
6.1.3 GROWING GERIATRIC POPULATION
6.1.4 INCREASING PRODUCT LAUNCHES AND EMERGENCE OF HOME TESTING DEVICES
6.2 RESTRAINTS
6.2.1 HIGH COST OF TESTING EQUIPMENT
6.2.2 TECHNOLOGICAL LIMITATION OF TESTING DEVICES
6.3 OPPORTUNITIES
6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING STRATEGIC INITIATIVES
6.3.3 GOVERNMENT INITIATIVES AND REIMBURSEMENT POLICIES
6.3.4 PRODUCT DEVELOPMENT FOR AT-HOME TESTING
6.4 CHALLENGES
6.4.1 LACK OF STANDARDIZATION AND VARIABILITY IN TEST RESULTS
6.4.2 LACK OF SKILLED PROFESSIONALS
7 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY TYPE
7.1 OVERVIEW
7.2 HARDWARE
7.2.1 PFT DEVICES
7.2.2 PFT ACCESSORIES & CONSUMABLES
7.2.2.1 Spirometry
7.2.2.2 Lung Volume in Unit/ Plethysmography Test
7.2.2.3 Gas Exchange Testing
7.2.2.4 Cardiopulmonary Exercise Test (CPET)
7.2.2.5 Pulse Oximetry Test
7.2.2.6 Diffusion Capacity Test
7.2.2.7 Maximal Voluntary Ventilation
7.2.2.8 Oxygen Titration Test
7.2.2.9 Respiratory Muscle Function
7.2.2.10 Bronchial Provocation Test
7.2.2.11 High Altitude Simulation Testing
7.2.3 OTHERS
7.2.3.1 3.2. Direct Tender
7.2.3.2 3.2. Retail Sales
7.2.4 OTHERS
7.3 SOFTWARE
7.4 SERVICES
8 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE
8.1 OVERVIEW
8.2 ADULT
8.2.1 MALE
8.2.2 FEMALE
8.3 GERIATRIC
8.3.1 MALE
8.3.2 FEMALE
8.4 PEDIATRIC
8.4.1 MALE
8.4.2 FEMALE
9 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 OBSTRUCTIVE LUNG DISEASE
9.2.1 ASTHMA
9.2.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
9.2.3 BRONCHIECTASIS
9.2.4 CYSTIC FIBROSIS
9.3 RESTRICTIVE LUNG DISEASE
9.3.1 LUNG CANCER
9.3.2 INTERSTITIAL LUNG DISEASE
9.3.3 AMYOTROPHIC LATERAL SCLEROSIS (ALS)
9.3.4 SCOLIOSIS
9.3.5 SARCOIDOSIS
9.3.6 MUSCULAR DYSTROPHY
10 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.2.1 PUBLIC
10.2.2 PRIVATE
10.3 SPECIALTY CLINICS
10.4 DIAGNOSTICS LABORATORIES
10.5 HOME CARE SETTINGS
10.6 OTHERS
11 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 VYAIRE MEDICAL, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENTS
14.2 TELEFLEX INCORPORATED
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO 166
14.2.5 RECENT DEVELOPMENT 166
14.3 CAIRE INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 COSMED SRL
14.4.1 COMPANY SNAPSHOT
14.4.2 COMPANY SHARE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENTS
14.5 SCHILLER AG
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENTS
14.6 CHEST M.I., INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 CLARITY MEDICAL
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 CONTEC MEDICAL SYSTEMS CO., LTD
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 DATA SCIENCES INTERNATIONAL.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 ECO MEDICS
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 FUKUDA SANGYO CO., LTD.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 GANSHORN MEDIZIN ELECTRONIC GMBH
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GERATHERM MEDICAL AG
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.14 INGMAR MEDICAL
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 INOFAB HEALTH (A CLARIO COMPANY)
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 JK MEDICAL SYSTEMS PVT LTD.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 KOKO, PFT
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 MEC
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 MEDICAL EQUIPMENT EUROPE GMBH
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENTS
14.2 MEDLINE
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 MORGAN SCIENTIFIC
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.22 NDD MEDICAL TECHNOLOGIES
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 PULMONE ADVANCED MEDICAL DEVICES
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENT
14.24 RECORDERS & MEDICARE SYSTEMS PRIVATE LIMITED
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT
14.25 SCIREQ
14.25.1 COMPANY SNAPSHOT
14.25.2 PRODUCT PORTFOLIO
14.25.3 RECENT DEVELOPMENT
14.26 SIBEL, S.A.U
14.26.1 COMPANY SNAPSHOT
14.26.2 PRODUCT PORTFOLIO
14.26.3 RECENT DEVELOPMENT
14.27 VITALOGRAPH
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 2 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (VOLUME IN UNIT)
TABLE 6 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 7 NORTH AMERICA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (VOLUME IN UNIT)
TABLE 9 NORTH AMERICA MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)
TABLE 11 NORTH AMERICA NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA SOFTWARE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA SERVICES IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN PULMONARY FUNCTION TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA DIAGNOSTICS LABORATORIES IN PULMONARY FUNCTION TESTING, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOME CARE SETTINGS IN PULMONARY FUNCTION TESTING, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA OTHERS IN PULMONARY FUNCTION TESTING, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 U.S. HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 59 U.S. PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 60 U.S. PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 61 U.S. PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 67 U.S. RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 U.S. PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 U.S. ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 U.S. PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 76 U.S. HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 CANADA PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 CANADA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 CANADA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 CANADA PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 81 CANADA PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 CANADA MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 CANADA ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 90 CANADA GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 91 CANADA PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 92 CANADA PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 93 CANADA OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 CANADA RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 95 CANADA PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 96 CANADA HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 MEXICO PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 MEXICO HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 MEXICO PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 MEXICO PFT DEVICES IN PULMONARY FUNCTION TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 101 MEXICO PFT ACCESSORIES & CONSUMABLES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 102 MEXICO MOUTHPIECE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 MEXICO ADULT IN PULMONARY FUNCTION TESTING MARKET, BY SIZE, 2022-2031 (USD THOUSAND)
TABLE 104 MEXICO NOSE CLIP IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 MEXICO HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 MEXICO HARDWARE IN PULMONARY FUNCTION TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 107 MEXICO RETAIL SALES IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 108 MEXICO PULMONARY FUNCTION TESTING MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 MEXICO ADULT IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 110 MEXICO GERIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 111 MEXICO PEDIATRIC IN PULMONARY FUNCTION TESTING MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 112 MEXICO PULMONARY FUNCTION TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 113 MEXICO OBSTRUCTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 114 MEXICO RESTRICTIVE LUNG DISEASE IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 MEXICO PULMONARY FUNCTION TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 116 MEXICO HOSPITAL IN PULMONARY FUNCTION TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET, BY TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 INCREASING PREVALENCE OF RESPIRATORY DISEASES IS DRIVING THE GROWTH OF THE NORTH AMERICA PULMONARY FUNCTION TESTING MARKET FROM 2024 TO 2031
FIGURE 15 THE HARDWARE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PULMONARY FUNCTION TESTING MARKET IN 2024 AND 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, 2023
FIGURE 18 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 19 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, 2023
FIGURE 22 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 23 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION 2023
FIGURE 26 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 27 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY END USER 2023
FIGURE 30 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 31 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: END USER, CAGR (2024-2031)
FIGURE 32 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: END USER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: SNAPSHOT (2023)
FIGURE 34 NORTH AMERICA PULMONARY FUNCTION TESTING MARKET: COMPANY SHARE 2023 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
